Your browser doesn't support javascript.
loading
Immunogenicity and protective efficacy of a co-formulated two-in-one inactivated whole virus particle COVID-19/influenza vaccine.
Handabile, Chimuka; Ohno, Marumi; Sekiya, Toshiki; Nomura, Naoki; Kawakita, Tomomi; Kawahara, Mamiko; Endo, Masafumi; Nishimura, Tomohiro; Okumura, Minako; Toba, Shinsuke; Sasaki, Michihito; Orba, Yasuko; Chua, Brendon Y; Rowntree, Louise C; Nguyen, Thi H O; Shingai, Masashi; Sato, Akihiko; Sawa, Hirofumi; Ogasawara, Kazumasa; Kedzierska, Katherine; Kida, Hiroshi.
Afiliação
  • Handabile C; Institute for Vaccine Research and Development (HU-IVReD), Hokkaido University, Sapporo, Japan.
  • Ohno M; Division of Biologics Development, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.
  • Sekiya T; Institute for Vaccine Research and Development (HU-IVReD), Hokkaido University, Sapporo, Japan.
  • Nomura N; Division of Biologics Development, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.
  • Kawakita T; One Health Research Center, Hokkaido University, Sapporo, Japan.
  • Kawahara M; Institute for Vaccine Research and Development (HU-IVReD), Hokkaido University, Sapporo, Japan.
  • Endo M; Division of Biologics Development, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.
  • Nishimura T; International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.
  • Okumura M; Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
  • Toba S; Institute for Vaccine Research and Development (HU-IVReD), Hokkaido University, Sapporo, Japan.
  • Sasaki M; Division of Biologics Development, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.
  • Orba Y; Division of International Research Promotion, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.
  • Chua BY; Institute for Vaccine Research and Development (HU-IVReD), Hokkaido University, Sapporo, Japan.
  • Rowntree LC; Division of Vaccine Immunology, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.
  • Nguyen THO; Division of Biologics Development, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.
  • Shingai M; KM Biologics Co. Ltd, Kumamoto, Japan.
  • Sato A; KM Biologics Co. Ltd, Kumamoto, Japan.
  • Sawa H; KM Biologics Co. Ltd, Kumamoto, Japan.
  • Ogasawara K; Shionogi Pharmaceutical Research Center, Shionogi & Company, Limited, Toyonaka, Japan.
  • Kedzierska K; Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.
  • Kida H; Institute for Vaccine Research and Development (HU-IVReD), Hokkaido University, Sapporo, Japan.
Sci Rep ; 14(1): 4204, 2024 02 20.
Article em En | MEDLINE | ID: mdl-38378856
ABSTRACT
Due to the synchronous circulation of seasonal influenza viruses and severe acute respiratory coronavirus 2 (SARS-CoV-2) which causes coronavirus disease 2019 (COVID-19), there is need for routine vaccination for both COVID-19 and influenza to reduce disease severity. Here, we prepared individual WPVs composed of formalin-inactivated SARS-CoV-2 WK 521 (Ancestral strain; Co WPV) or influenza virus [A/California/07/2009 (X-179A) (H1N1) pdm; Flu WPV] to produce a two-in-one Co/Flu WPV. Serum analysis from vaccinated mice revealed that a single dose of Co/Flu WPV induced antigen-specific neutralizing antibodies against both viruses, similar to those induced by either type of WPV alone. Following infection with either virus, mice vaccinated with Co/Flu WPV showed no weight loss, reduced pneumonia and viral titers in the lung, and lower gene expression of proinflammatory cytokines, as observed with individual WPV-vaccinated. Furthermore, a pentavalent vaccine (Co/qFlu WPV) comprising of Co WPV and quadrivalent influenza vaccine (qFlu WPV) was immunogenic and protected animals from severe COVID-19. These results suggest that a single dose of the two-in-one WPV provides efficient protection against SARS-CoV-2 and influenza virus infections with no evidence of vaccine interference in mice. We propose that concomitant vaccination with the two-in-one WPV can be useful for controlling both diseases.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas contra Influenza / Influenza Humana / Vírus da Influenza A Subtipo H1N1 / COVID-19 Limite: Animals / Humans Idioma: En Revista: Sci Rep Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Japão País de publicação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas contra Influenza / Influenza Humana / Vírus da Influenza A Subtipo H1N1 / COVID-19 Limite: Animals / Humans Idioma: En Revista: Sci Rep Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Japão País de publicação: Reino Unido